Skip to main content
Clinical Trials/NCT06773013
NCT06773013
Completed
N/A

Safety and Effectiveness of Sonu Acoustic Resonance Therapy for the Treatment of Pediatric Patients With Moderate to Severe Nasal Congestion.

Third Wave Therapeutics1 site in 1 country31 target enrollmentJanuary 9, 2025

Overview

Phase
N/A
Intervention
Not specified
Conditions
Nasal Congestion and Inflammations
Sponsor
Third Wave Therapeutics
Enrollment
31
Locations
1
Primary Endpoint
Serious adverse events
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

To demonstrate the safety and effectiveness of Sonu for the treatment of pediatric patients with moderate to severe nasal congestion.

Registry
clinicaltrials.gov
Start Date
January 9, 2025
End Date
March 30, 2025
Last Updated
7 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Third Wave Therapeutics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pediatric subjects between the ages of 12 to 21 years
  • Present with symptoms of nasal congestion for 1 month or more prior to treatment
  • Have a 24 hour reflective nasal congestion subscore of the TNSS of 2 or more on a 0 to 3 scale at the time of screening

Exclusion Criteria

  • Head, nasal or sinus surgery within 3 months
  • Sinus infection diagnosed within the last month, or rhinitis medicamentosa
  • Documented history of nasal polyposis or mass
  • Pregnancy

Outcomes

Primary Outcomes

Serious adverse events

Time Frame: 2 weeks

Safety

Reduction in nasal congestion subscore

Time Frame: 2 weeks

Effectiveness

Secondary Outcomes

  • Adverse events(2 weeks)
  • Total Nasal Symptom Score (TNSS)(2 weeks)

Study Sites (1)

Loading locations...

Similar Trials